JP2017533218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533218A5 JP2017533218A5 JP2017523438A JP2017523438A JP2017533218A5 JP 2017533218 A5 JP2017533218 A5 JP 2017533218A5 JP 2017523438 A JP2017523438 A JP 2017523438A JP 2017523438 A JP2017523438 A JP 2017523438A JP 2017533218 A5 JP2017533218 A5 JP 2017533218A5
- Authority
- JP
- Japan
- Prior art keywords
- alanine
- acetyl
- composition according
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 32
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims 19
- 235000001014 amino acid Nutrition 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 108010059993 Vancomycin Proteins 0.000 claims 12
- 229960003165 vancomycin Drugs 0.000 claims 12
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 11
- 239000004472 Lysine Substances 0.000 claims 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 9
- 229960003104 ornithine Drugs 0.000 claims 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 8
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims 8
- 239000000654 additive Substances 0.000 claims 8
- 230000000996 additive effect Effects 0.000 claims 8
- 235000005772 leucine Nutrition 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 235000009697 arginine Nutrition 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 235000018977 lysine Nutrition 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 235000004400 serine Nutrition 0.000 claims 7
- 239000004474 valine Substances 0.000 claims 7
- 235000014393 valine Nutrition 0.000 claims 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- 235000004279 alanine Nutrition 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 2
- 229930182831 D-valine Natural products 0.000 claims 2
- 235000019766 L-Lysine Nutrition 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 229930064664 L-arginine Natural products 0.000 claims 2
- 235000014852 L-arginine Nutrition 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 108010053950 Teicoplanin Proteins 0.000 claims 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 2
- 229960002488 dalbavancin Drugs 0.000 claims 2
- 108700009376 dalbavancin Proteins 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229960001607 oritavancin Drugs 0.000 claims 2
- 108010006945 oritavancin Proteins 0.000 claims 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 2
- 229960001608 teicoplanin Drugs 0.000 claims 2
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 229960005240 telavancin Drugs 0.000 claims 1
- 108010089019 telavancin Proteins 0.000 claims 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 1
- -1 teravancin Chemical compound 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076400P | 2014-11-06 | 2014-11-06 | |
| US62/076,400 | 2014-11-06 | ||
| US201562168749P | 2015-05-30 | 2015-05-30 | |
| US62/168,749 | 2015-05-30 | ||
| PCT/EP2015/075918 WO2016071495A1 (en) | 2014-11-06 | 2015-11-06 | Glycopeptide compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020123671A Division JP7032488B2 (ja) | 2014-11-06 | 2020-07-20 | グリコペプチド組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533218A JP2017533218A (ja) | 2017-11-09 |
| JP2017533218A5 true JP2017533218A5 (OSRAM) | 2018-10-25 |
| JP6797795B2 JP6797795B2 (ja) | 2020-12-09 |
Family
ID=54478023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523438A Active JP6797795B2 (ja) | 2014-11-06 | 2015-11-06 | グリコペプチド組成物 |
| JP2020123671A Active JP7032488B2 (ja) | 2014-11-06 | 2020-07-20 | グリコペプチド組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020123671A Active JP7032488B2 (ja) | 2014-11-06 | 2020-07-20 | グリコペプチド組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US10188697B2 (OSRAM) |
| EP (4) | EP3542812B1 (OSRAM) |
| JP (2) | JP6797795B2 (OSRAM) |
| KR (2) | KR102763211B1 (OSRAM) |
| CN (1) | CN107073072B (OSRAM) |
| AU (1) | AU2015341763B2 (OSRAM) |
| BR (1) | BR112017009405B1 (OSRAM) |
| CL (1) | CL2017001139A1 (OSRAM) |
| CO (1) | CO2017005391A2 (OSRAM) |
| CR (1) | CR20170234A (OSRAM) |
| CY (2) | CY1122960T1 (OSRAM) |
| DK (2) | DK3542812T3 (OSRAM) |
| EA (1) | EA035368B1 (OSRAM) |
| ES (2) | ES2769849T3 (OSRAM) |
| HR (2) | HRP20200101T1 (OSRAM) |
| HU (2) | HUE049857T2 (OSRAM) |
| IL (1) | IL252120B (OSRAM) |
| MX (1) | MX387229B (OSRAM) |
| NZ (1) | NZ731955A (OSRAM) |
| PH (1) | PH12017500720A1 (OSRAM) |
| PL (2) | PL3215173T3 (OSRAM) |
| PT (2) | PT3542812T (OSRAM) |
| RS (2) | RS59851B1 (OSRAM) |
| SA (1) | SA517381446B1 (OSRAM) |
| SG (1) | SG11201703568WA (OSRAM) |
| SI (2) | SI3542812T1 (OSRAM) |
| TN (1) | TN2017000182A1 (OSRAM) |
| WO (1) | WO2016071495A1 (OSRAM) |
| ZA (1) | ZA201702767B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6797795B2 (ja) * | 2014-11-06 | 2020-12-09 | クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ | グリコペプチド組成物 |
| ES3028295T3 (en) * | 2015-12-24 | 2025-06-18 | Univ Leiden | Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject |
| MX388732B (es) * | 2016-05-09 | 2025-03-20 | Xellia Pharmaceuticals Aps | Formulaciones de antibioticos glicopeptidicos estabilizados |
| EP3544616A4 (en) * | 2016-11-23 | 2020-12-09 | Gufic Biosciences Limited | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN |
| JP7118412B2 (ja) * | 2017-07-31 | 2022-08-16 | 東洋製薬化成株式会社 | バンコマイシン懸濁液充填カプセル製剤 |
| CN109725101B (zh) * | 2017-10-31 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
| CN109078001B (zh) * | 2018-09-21 | 2021-05-07 | 深圳浦瑞健康科技有限公司 | 一种万古霉素纳米脂质体组合物及其制备方法 |
| US20220184173A1 (en) | 2019-03-08 | 2022-06-16 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| US11433115B2 (en) * | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014969A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| WO2022234036A1 (en) * | 2021-05-07 | 2022-11-10 | Xellia Pharmaceuticals Aps | Oral liquid vancomycin formulations |
| CN115804832A (zh) * | 2021-09-14 | 2023-03-17 | 海南普利制药股份有限公司 | 一种万古霉素水溶液组合物 |
| JPWO2023171588A1 (OSRAM) * | 2022-03-08 | 2023-09-14 | ||
| GB202207345D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| GB202207344D0 (en) | 2022-05-19 | 2022-07-06 | Arecor Ltd | Novel composition |
| WO2024079224A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| AU2023359652A1 (en) * | 2022-10-12 | 2025-05-29 | Hikma Pharmaceuticals Usa Inc. | Liquid dalbavancin composition |
| WO2025006267A1 (en) * | 2023-06-26 | 2025-01-02 | Venn Biosciences Corporation | Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis |
| GB202405997D0 (en) | 2024-04-29 | 2024-06-12 | Arecor Ltd | Novel compositions |
| GB202405996D0 (en) | 2024-04-29 | 2024-06-12 | Arecor Ltd | Novel compositions |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670258A (en) | 1984-02-10 | 1987-06-02 | Vanderbilt University | Storable prepackaged aqueous solutions of vancomycin |
| RU2145609C1 (ru) | 1994-01-28 | 2000-02-20 | Эли Лилли Энд Компани | Производные гликопептида или их соли, способ получения, фармацевтическая композиция |
| WO1997019690A1 (en) | 1995-12-01 | 1997-06-05 | Eli Lilly And Company | Stable vancomycin hydrochloride solutions |
| JPH1180021A (ja) | 1997-09-02 | 1999-03-23 | Kayaku:Kk | バンコマイシン注射剤 |
| US6800608B2 (en) | 2001-06-22 | 2004-10-05 | Beckman Coulter, Inc. | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator |
| WO2003082273A1 (en) * | 2002-03-26 | 2003-10-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Solubilization of weak bases |
| GB0212622D0 (en) * | 2002-05-31 | 2002-07-10 | Natural Technologies Group Ltd | Bacterial transforming agent |
| EP1578362A4 (en) | 2002-07-09 | 2008-11-05 | Point Therapeutics Inc | COMBINATION THERAPY WITH A BOROPROLINE COMPOUND |
| CN1802090A (zh) * | 2002-07-09 | 2006-07-12 | 尖端医疗有限公司 | 硼脯氨酸化合物组合治疗 |
| KR20120056310A (ko) | 2002-11-18 | 2012-06-01 | 비큐론 파마세티컬스 인코포레이티드 | 박테리아 감염 치료를 위한 달바반신 투여 방법 |
| UA91208C2 (ru) | 2005-02-14 | 2010-07-12 | Венус Ремедиз Лимитед | Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний |
| CN1857716A (zh) * | 2006-03-14 | 2006-11-08 | 浙江大学 | 注射用盐酸万古霉素及其制备方法 |
| JP2008201778A (ja) | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| CN102026666B (zh) * | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发（河北）有限公司 | 促胰岛素肽缀合物制剂 |
| JP2011080021A (ja) | 2009-10-09 | 2011-04-21 | Bridgestone Corp | 熱可塑性エラストマー組成物及びその成形体 |
| CA2836643C (en) * | 2011-05-19 | 2017-11-14 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
| WO2014026052A1 (en) | 2012-08-08 | 2014-02-13 | Vanderbilt University | Composition with biofilm dispersal agents |
| US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| WO2014194296A1 (en) * | 2013-05-30 | 2014-12-04 | Scidose, Llc | Formulations of vancomycin |
| CN106573037A (zh) | 2014-03-14 | 2017-04-19 | 库蒂斯制药公司 | 用于万古霉素口服液的组合物和方法 |
| JP6797795B2 (ja) * | 2014-11-06 | 2020-12-09 | クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ | グリコペプチド組成物 |
| MX388732B (es) | 2016-05-09 | 2025-03-20 | Xellia Pharmaceuticals Aps | Formulaciones de antibioticos glicopeptidicos estabilizados |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
-
2015
- 2015-11-06 JP JP2017523438A patent/JP6797795B2/ja active Active
- 2015-11-06 PT PT191748490T patent/PT3542812T/pt unknown
- 2015-11-06 PT PT157912874T patent/PT3215173T/pt unknown
- 2015-11-06 EP EP19174849.0A patent/EP3542812B1/en active Active
- 2015-11-06 KR KR1020237020985A patent/KR102763211B1/ko active Active
- 2015-11-06 KR KR1020177015221A patent/KR102603756B1/ko active Active
- 2015-11-06 US US15/524,653 patent/US10188697B2/en active Active
- 2015-11-06 NZ NZ731955A patent/NZ731955A/en unknown
- 2015-11-06 CN CN201580060330.2A patent/CN107073072B/zh active Active
- 2015-11-06 DK DK19174849.0T patent/DK3542812T3/da active
- 2015-11-06 PL PL15791287T patent/PL3215173T3/pl unknown
- 2015-11-06 BR BR112017009405-3A patent/BR112017009405B1/pt active IP Right Grant
- 2015-11-06 WO PCT/EP2015/075918 patent/WO2016071495A1/en not_active Ceased
- 2015-11-06 ES ES15791287T patent/ES2769849T3/es active Active
- 2015-11-06 HU HUE15791287A patent/HUE049857T2/hu unknown
- 2015-11-06 EP EP20215453.0A patent/EP3834837A1/en not_active Withdrawn
- 2015-11-06 EP EP22203229.4A patent/EP4147710A1/en active Pending
- 2015-11-06 MX MX2017005749A patent/MX387229B/es unknown
- 2015-11-06 SI SI201531539T patent/SI3542812T1/sl unknown
- 2015-11-06 HR HRP20200101TT patent/HRP20200101T1/hr unknown
- 2015-11-06 RS RS20200080A patent/RS59851B1/sr unknown
- 2015-11-06 SG SG11201703568WA patent/SG11201703568WA/en unknown
- 2015-11-06 ES ES19174849T patent/ES2852550T3/es active Active
- 2015-11-06 PL PL19174849T patent/PL3542812T3/pl unknown
- 2015-11-06 HU HUE19174849A patent/HUE053347T2/hu unknown
- 2015-11-06 EP EP15791287.4A patent/EP3215173B8/en not_active Revoked
- 2015-11-06 RS RS20210108A patent/RS61418B1/sr unknown
- 2015-11-06 TN TN2017000182A patent/TN2017000182A1/en unknown
- 2015-11-06 SI SI201531067T patent/SI3215173T1/sl unknown
- 2015-11-06 EA EA201790997A patent/EA035368B1/ru unknown
- 2015-11-06 CR CR20170234A patent/CR20170234A/es unknown
- 2015-11-06 AU AU2015341763A patent/AU2015341763B2/en active Active
- 2015-11-06 DK DK15791287.4T patent/DK3215173T3/da active
-
2017
- 2017-04-18 PH PH12017500720A patent/PH12017500720A1/en unknown
- 2017-04-19 ZA ZA2017/02767A patent/ZA201702767B/en unknown
- 2017-05-01 SA SA517381446A patent/SA517381446B1/ar unknown
- 2017-05-04 IL IL252120A patent/IL252120B/en active IP Right Grant
- 2017-05-05 CL CL2017001139A patent/CL2017001139A1/es unknown
- 2017-05-26 CO CONC2017/0005391A patent/CO2017005391A2/es unknown
- 2017-11-30 US US15/827,719 patent/US10039804B2/en active Active
-
2018
- 2018-12-11 US US16/216,446 patent/US10849956B2/en active Active
-
2019
- 2019-11-07 US US16/677,057 patent/US11000567B2/en active Active
-
2020
- 2020-03-20 CY CY20201100266T patent/CY1122960T1/el unknown
- 2020-07-20 JP JP2020123671A patent/JP7032488B2/ja active Active
-
2021
- 2021-03-01 HR HRP20210342TT patent/HRP20210342T8/hr unknown
- 2021-03-29 US US17/215,675 patent/US11628200B2/en active Active
- 2021-04-09 CY CY20211100307T patent/CY1124011T1/el unknown
-
2022
- 2022-07-08 US US17/860,642 patent/US11517609B2/en active Active
-
2023
- 2023-01-06 US US18/151,155 patent/US12161690B2/en active Active
-
2024
- 2024-10-30 US US18/932,117 patent/US20250288640A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533218A5 (OSRAM) | ||
| HRP20210342T1 (hr) | Pripravci glikopeptida | |
| JP2019518733A5 (OSRAM) | ||
| Matougui et al. | Lipid-based nanoformulations for peptide delivery | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP2013525484A5 (OSRAM) | ||
| WO2007135196A3 (en) | Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0 | |
| MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| EA201591276A1 (ru) | Фармацевтическая композиция с улучшенной биодоступностью | |
| MY192981A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| WO2010051541A3 (en) | Compositions containing delta-9-thc-amino acid esters and process of preparation | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| EP3378486A3 (en) | Stabilized antibody-containing liquid formulations | |
| JP2017222654A5 (OSRAM) | ||
| EA201490847A1 (ru) | Аминокислотные производные, функционализованные на n конце, способные образовывать микросферы, инкапсулирующие лекарственное средство | |
| EA201492021A1 (ru) | Антительный состав | |
| BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
| BR112012027055A8 (pt) | agente estabilizante para proteínas farmacêuticas. | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
| MY149924A (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| EA201792144A1 (ru) | Стабильный препарат для парентерального введения тапентадола | |
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) |